Yan Junqiang, Liu Anran, Huang Jiarui, Wu Jiannan, Shen Ruile, Ma Hongxia, Yang Jianxue
Key Laboratory of Neuromolecular Biology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China.
Department of Neurology, The First Affiliated Hospital, College of Clinical Medicine of Henan University of Science and Technology, Luoyang, China.
Front Aging Neurosci. 2021 Aug 13;13:709878. doi: 10.3389/fnagi.2021.709878. eCollection 2021.
To review the therapeutic effects of drugs on REM sleep behavior disorder (RBD) in Parkinson's disease (PD) by searching the MEDLINE/PubMed, Embase, Cochrane, and CBM databases. According to the inclusion and exclusion criteria, studies were included after excluding duplicate data. We evaluated the safety and efficacy of pharmacological intervention to improve RBD in patients with Parkinson's disease (PD-RBD). This systematic review mainly describes the drugs that can be used to treat PD-RBD patients. The results have shown that melatonin can be used as the first-line drug for PD-RBD, and clonazepam provides significant improvement on PD-RBD, androtigotine can be used as an alternative drug. However, further large-scale clinical trial studies are still needed to provide the best guidelines for the pharmacological treatment of PD-RBD.
通过检索MEDLINE/PubMed、Embase、Cochrane和中国生物医学文献数据库（CBM），回顾药物对帕金森病（PD）快速眼动睡眠行为障碍（RBD）的治疗效果。根据纳入和排除标准，排除重复数据后纳入研究。我们评估了药物干预改善帕金森病RBD患者（PD-RBD）的安全性和有效性。本系统评价主要描述了可用于治疗PD-RBD患者的药物。结果表明，褪黑素可作为PD-RBD的一线药物，氯硝西泮对PD-RBD有显著改善作用，罗替戈汀可作为替代药物。然而，仍需要进一步的大规模临床试验研究，为PD-RBD的药物治疗提供最佳指导原则。
